AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17401488 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression with tacrolimus, azathioprine and prednisone (GI, N = 38)
Number of subjects: 92
Study 17401488 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of daclizumab, mycophenolate mofetil (MMF), and prednisone (GII, N = 33)
Number of subjects: 92
Study 17401488 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of daclizumab, MMF, sirolimus and prednisone (GIII, N = 21)
Number of subjects: 92
Study 17401488 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients of black ethnicity
Number of subjects: 92
Study 17401488 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of post-transplant diabetes mellitus
Number of subjects: 92
Study 17401488 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of cytomegalovirus disease
Number of subjects: 92
Study 14653099 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy with drugs
Number of subjects: 96
Study 14653099 — intervention group
Group type: COMPARATOR
Intervention: Drugs (control group)
Number of subjects: 96
Study 10834687 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg at 8-hr intervals through nasogastric tube)
Number of subjects: 305
Study 10834687 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered at 8-hr intervals through nasogastric tube)
Number of subjects: 305
Study 10834687 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 305
Study 10834687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 8863918 — intervention group
Group type: EXPERIMENTAL
Intervention: Homosexual AIDS patients
Number of subjects: 102
Study 8863918 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukaemia patients
Number of subjects: 102
Study 8863918 — intervention group
Group type: EXPERIMENTAL
Intervention: All variables
Number of subjects: 102
Study 1736128 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy in a thermomineral institution
Number of subjects: 46
Study 1736128 — intervention group
Group type: COMPARATOR
Intervention: Hydrotherapy in a hospital exercise-bath (control group)
Number of subjects: 46
Study 6743506 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening (clinical examination every year and mammography on alternate years)
Number of subjects: 65000
Study 6743506 — intervention group
Group type: COMPARATOR
Intervention: Control (non-screening group)
Number of subjects: 65000
Study 2876326 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoeopathic preparation of mixed grass pollens
Number of subjects: 144
Study 2876326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 29311020 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision and drainage along with oral antibiotics
Number of subjects: 40
Study 29311020 — intervention group
Group type: COMPARATOR
Intervention: Incision and drainage only
Number of subjects: 40
Study 27571256 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (continuous infusion at a rate of 0.1 μg kg h; n = 38)
Number of subjects: 76
Study 27571256 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 38)
Number of subjects: 76
Study 27571256 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (n = 38)
Number of subjects: 76
Study 24943245 — intervention group
Group type: EXPERIMENTAL
Intervention: RMN-guided single-ring ablation
Number of subjects: 80
Study 24943245 — intervention group
Group type: COMPARATOR
Intervention: RMN-guided circumferential PVA
Number of subjects: 80
Study 22228112 — intervention group
Group type: COMPARATOR
Intervention: P0 (0 seconds interrepetition rest)
Number of subjects: 10
Study 22228112 — intervention group
Group type: EXPERIMENTAL
Intervention: P20 (20 seconds interrepetition rest)
Number of subjects: 10
Study 22228112 — intervention group
Group type: EXPERIMENTAL
Intervention: P40 (40 seconds interrepetition rest)
Number of subjects: 10
Study 20719923 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLD responses to objects presented in the upper visual field (UVF)
Number of subjects: 0
Study 20719923 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLD responses to scrambled objects presented in the upper visual field (UVF)
Number of subjects: 0
Study 20719923 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLD responses to objects presented in the lower visual field (LVF)
Number of subjects: 0
Study 20719923 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLD responses to scrambled objects presented in the lower visual field (LVF)
Number of subjects: 0
Study 20719923 — intervention group
Group type: COMPARATOR
Intervention: Comparison of BOLD responses to objects versus scrambled objects in both UVF and LVF
Number of subjects: 0
Study 18565744 — intervention group
Group type: EXPERIMENTAL
Intervention: 64 Gy in 32 fractions over 6.5 weeks
Number of subjects: 843
Study 18565744 — intervention group
Group type: COMPARATOR
Intervention: 74 Gy in 37 fractions over 7.5 weeks
Number of subjects: 843
Study 18565744 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of electronic portal imaging (EPI)
Number of subjects: 843
Study 18565744 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of low melting point alloy (LMPA) blocks
Number of subjects: 843
Study 16168871 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior Walking Environmental Assessment Tool (SWEAT)
Number of subjects: 355
Study 12795572 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused psychoeducational therapy (n = 28)
Number of subjects: 53
Study 12795572 — intervention group
Group type: COMPARATOR
Intervention: Individual treatment (n = 25)
Number of subjects: 53
Study 10819853 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed pushing
Number of subjects: 1862
Study 8793675 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm blood cardioplegia (37 degrees C)
Number of subjects: 40
Study 8793675 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia (4 degrees C)
Number of subjects: 40
Study 1352930 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily for 4 weeks, then 40 mg daily for another 4 weeks
Number of subjects: 24
Study 1352930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6498044 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 100
Study 6498044 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine
Number of subjects: 100
Study 6498044 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% etidocaine
Number of subjects: 100
Study 6498044 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine groups (0.5% and 0.75%)
Number of subjects: 100
Study 30499599 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogen-reduced platelet concentrates (Mirasol)
Number of subjects: 448
Study 30499599 — intervention group
Group type: COMPARATOR
Intervention: Untreated platelet concentrates
Number of subjects: 448
Study 30113651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin at 10 mg
Number of subjects: 46
Study 30113651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 30113651 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin at 10 mg
Number of subjects: 46
Study 27208669 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling intervention delivered by family doctors
Number of subjects: 137
Study 27208669 — intervention group
Group type: EXPERIMENTAL
Intervention: Favourable doctor communication
Number of subjects: 137
Study 27208669 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of the abuse and readiness for help
Number of subjects: 137
Study 27208669 — intervention group
Group type: EXPERIMENTAL
Intervention: Weave as an avenue to help
Number of subjects: 137
Study 27208669 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor's communication
Number of subjects: 137
Study 27208669 — intervention group
Group type: EXPERIMENTAL
Intervention: Role in providing care for IPV
Number of subjects: 137
Study 27208669 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional health
Number of subjects: 137
Study 27208669 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctors' time
Number of subjects: 137
Study 27208669 — intervention group
Group type: EXPERIMENTAL
Intervention: Managing the disclosure process
Number of subjects: 137
Study 27208669 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing primary care as a safe option
Number of subjects: 137
Study 25332247 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab plus docetaxel
Number of subjects: 808
Study 25332247 — intervention group
Group type: COMPARATOR
Intervention: Control: Placebo plus trastuzumab plus docetaxel
Number of subjects: 808
Study 25332247 — intervention group
Group type: EXPERIMENTAL
Intervention: High HER2 protein, high HER2 and HER3 mRNA levels, wild-type PIK3CA, low sHER2
Number of subjects: 808
Study 22190020 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic load diet (mean GL/d = 125)
Number of subjects: 80
Study 22190020 — intervention group
Group type: COMPARATOR
Intervention: High-glycemic load diet (mean GL/d = 250)
Number of subjects: 80
Study 20506154 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal embolic protection (PEP) during angioplasty
Number of subjects: 31
Study 20506154 — intervention group
Group type: COMPARATOR
Intervention: No proximal embolic protection (without PEP) during angioplasty
Number of subjects: 31
Study 18227304 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hyperpnoea (IH)
Number of subjects: 30
Study 18227304 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 30
Study 16450596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1.5 mg/kg IV)
Number of subjects: 37
Study 16450596 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic saline (1 liter)
Number of subjects: 37
Study 16450596 — intervention group
Group type: COMPARATOR
Intervention: Conventional maintenance fluids (Control)
Number of subjects: 37
Study 12826169 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/d (po) plus vitamin D (800 UI cholecalciferol) and calcium (2.5 g of CaCO3)
Number of subjects: 14
Study 12826169 — intervention group
Group type: COMPARATOR
Intervention: Control group (vitamin D plus calcium at the same dose)
Number of subjects: 14
Study 10760045 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐α (IFN‐α)
Number of subjects: 144
Study 10760045 — intervention group
Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 144
Study 8799780 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 1 g oral dose of azithromycin (Group A)
Number of subjects: 200
Study 8799780 — intervention group
Group type: COMPARATOR
Intervention: Standard duration therapy (Group S)
Number of subjects: 200
Study 1386071 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (0.1 mg/kg) plus ipratropium bromide (50 micrograms)
Number of subjects: 61
Study 1386071 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol (0.1 mg/kg) and placebo
Number of subjects: 61
Study 6364761 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 194
Study 6364761 — intervention group
Group type: COMPARATOR
Intervention: Surgical therapy (CABG)
Number of subjects: 194
Study 30821649 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based Cognitive Behavioral Therapy (CBT)
Number of subjects: 11
Study 30821649 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 11
Study 29730798 — intervention group
Group type: EXPERIMENTAL
Intervention: Infratrochlear nerve block (ITB)
Number of subjects: 60
Study 29730798 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment without a nerve block)
Number of subjects: 60
Study 27543364 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin cream 12.5%
Number of subjects: 23
Study 27543364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 27543364 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin cream 0.5%
Number of subjects: 23
Study 27543364 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin cream 2.5%
Number of subjects: 23
Study 24629911 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary olestra (15 g/day)
Number of subjects: 28
Study 24629911 — intervention group
Group type: COMPARATOR
Intervention: Vegetable oil (VO)
Number of subjects: 28
Study 22409921 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Huoxue Granule
Number of subjects: 120
Study 22409921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20941469 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 0
Study 20941469 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose statin therapy
Number of subjects: 0
Study 20941469 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin plus ezetimibe
Number of subjects: 0
Study 18525297 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy with concurrent daily platinum chemotherapy (77 Gy, 1.1 Gy bid)
Number of subjects: 289
Study 18525297 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy without concurrent chemotherapy (70 Gy, 1.8‐2.0 Gy per fraction)
Number of subjects: 289
Study 16005555 — intervention group
Group type: EXPERIMENTAL
Intervention: Sidestepping trials with neuromuscular control training
Number of subjects: 20
Study 16005555 — intervention group
Group type: EXPERIMENTAL
Intervention: Sidestepping trials
Number of subjects: 20
Study 12447516 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium-induced curarization with no response at orbicularis oculi to TOF stimulation (group 1)
Number of subjects: 102
Study 12447516 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium-induced curarization with two responses at orbicularis oculi to TOF stimulation (group 2)
Number of subjects: 102
Study 10071177 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of d‐Fenfluramine (d‐Fen)
Number of subjects: 40
Study 10071177 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of Ipsapirone (Ips)
Number of subjects: 40
Study 10071177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8868007 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxatidine 150 mg
Number of subjects: 215
Study 8868007 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg
Number of subjects: 215
Study 2347956 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 0.5 g IV without probenecid
Number of subjects: 6
Study 2347956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 0.5 g IV with probenecid (0.5 g at 10 and 2 hours prior to ceftriaxone and 0.5 g q12h X 3 doses post ceftriaxone)
Number of subjects: 6
Study 23135 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazepam (30 mg orally)
Number of subjects: 6
Study 23135 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide (30 mg orally)
Number of subjects: 6
Study 23135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31404033 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) treatment using the Valeda Light Delivery System, 3 times per week for 3-4 weeks over 1 year.
Number of subjects: 30
Study 31404033 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) treatment
Number of subjects: 30
Study 31404033 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 30
Study 30723886 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane, increasing concentrations technique (Group A)
Number of subjects: 60
Study 30723886 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane, vital capacity technique (Group B)
Number of subjects: 60
Study 30723886 — intervention group
Group type: COMPARATOR
Intervention: Intravenous propofol (Group C)
Number of subjects: 60
Study 27741377 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha cradle (AC) immobilisation system
Number of subjects: 0
Study 27741377 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum bag (VB) immobilisation system
Number of subjects: 0
Study 27741377 — intervention group
Group type: EXPERIMENTAL
Intervention: Head rest and base plate (HB) immobilisation system
Number of subjects: 0
Study 27741377 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 26147563 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment
Number of subjects: 63
Study 26147563 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 63
Study 24274210 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-soaked biodegradable synthetic polyurethane foam
Number of subjects: 63
Study 24274210 — intervention group
Group type: COMPARATOR
Intervention: Saline-soaked polyurethane foam
Number of subjects: 63
Study 22108353 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphakic contact lenses (CL)
Number of subjects: 83
Study 22108353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular lenses (IOL)
Number of subjects: 83
Study 22108353 — intervention group
Group type: COMPARATOR
Intervention: Overall (both CL and IOL)
Number of subjects: 83
Study 18413006 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured triglycerides (Group A)
Number of subjects: 45
Study 18413006 — intervention group
Group type: COMPARATOR
Intervention: MCT/LCT emulsion (Group B)
Number of subjects: 45
Study 18413006 — intervention group
Group type: COMPARATOR
Intervention: LCT emulsion (Group C)
Number of subjects: 45
Study 15975964 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg every 2 weeks, subcutaneously) for 12 months
Number of subjects: 49
Study 12874091 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg/d) administered in the morning
Number of subjects: 90
Study 12874091 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg/d) administered at bedtime
Number of subjects: 90
Study 12874091 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan administered at bedtime
Number of subjects: 90
Study 12874091 — intervention group
Group type: COMPARATOR
Intervention: Valsartan administered in the morning vs bedtime
Number of subjects: 90
Study 10859151 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tablet dosing of rosiglitazone
Number of subjects: 0
Study 10859151 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution dosing of rosiglitazone
Number of subjects: 0
Study 10859151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dosing of rosiglitazone
Number of subjects: 0
Study 10859151 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and intravenous dosing of rosiglitazone
Number of subjects: 0
Study 10859151 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations of rosiglitazone
Number of subjects: 0
Study 9695144 — intervention group
Group type: EXPERIMENTAL
Intervention: Diskhaler
Number of subjects: 10
Study 9695144 — intervention group
Group type: EXPERIMENTAL
Intervention: Easi‐Breathe
Number of subjects: 10
Study 9695144 — intervention group
Group type: COMPARATOR
Intervention: Diskus
Number of subjects: 10
Study 8026109 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil product with a high percentage of omega-3-polyunsaturated fatty acids (K 85, 6g daily)
Number of subjects: 32
Study 8026109 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (6g daily)
Number of subjects: 32
Study 2483237 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulants
Number of subjects: 0
Study 2483237 — intervention group
Group type: COMPARATOR
Intervention: Low-dose heparin (12,500 i.u. daily by subcutaneous route)
Number of subjects: 0
Study 790128 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mg raubasine
Number of subjects: 26
Study 790128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31109172 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled aztreonam
Number of subjects: 0
Study 31109172 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27987252 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR342434 solution
Number of subjects: 30
Study 27987252 — intervention group
Group type: EXPERIMENTAL
Intervention: US-approved Humalog
Number of subjects: 30
Study 27987252 — intervention group
Group type: EXPERIMENTAL
Intervention: EU-approved Humalog
Number of subjects: 30
Study 25803777 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate 50 mg in 10 cc, self-administered 3 times daily at meal times
Number of subjects: 72
Study 25803777 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identically appearing)
Number of subjects: 72
Study 24339684 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCE with PCIOL implantation
Number of subjects: 115
Study 24339684 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification with PCIOL implantation
Number of subjects: 115
Study 21183763 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy (325 mg aspirin orally and a loading dose of 600 mg clopidogrel)
Number of subjects: 36
Study 21183763 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive strategy (same aspirin and clopidogrel as conventional, plus intravenous glycoprotein IIb/IIIa inhibitor)
Number of subjects: 36
Study 21183763 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy
Number of subjects: 36
Study 21183763 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive strategy
Number of subjects: 36
Study 19235600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 20
Study 19235600 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 20
Study 17726250 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 5000 U/day
Number of subjects: 150
Study 17726250 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) 5000 IU/day, two times a day
Number of subjects: 150
Study 17726250 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control group)
Number of subjects: 150
Study 15102080 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human alpha‐galactosidase A (r‐halphaGalA), administered i.v. at 1 mg per kg every 2 weeks for 5 months (Phase 3 trial)
Number of subjects: 58
Study 15102080 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 58